Literature DB >> 26205471

Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients.

Giulia Partipilo1, Giovanni Simone2, Anna Scattone2, Emanuela Scarpi3, Amalia Azzariti4, Anita Mangia1.   

Abstract

Understanding the expression of proteins involved in DNA damage response could improve knowledge of the pathways that contribute to familial and sporadic breast cancer (BC). We aimed to assess the different roles of BRCA1, poly(ADP-ribose) polymerase-1 (PARP1), BRCT-repeat inhibitor of hTERT expression (BRIT1) and novel SWItch 5 (SWI5) expression in 130 sporadic and 73 familial BC samples, by immunohistochemistry. In the sporadic group, negative nuclear BRCA1 (nBRCA1) expression was associated with positive PgR (p = 0.037). Negative association was found between nBRCA1 expression and HER2 (p = 0.001). In the familial group, nBRCA1 expression was associated with ER (p = 0.002). Reduced nBRCA1 expression was associated with higher histological grade and positive Ki67 both in sporadic (p = 0.0010, p = 0.047) and familial groups (p < 0.001, p = 0.001). Nuclear PARP1 (nPARP1) expression was associated with histological grade (p = 0.035) and positive PgR (p = 0.047) in sporadic cases. High cytoplasmic and low nuclear BRIT1 (cBRIT1 and nBRIT1) expression were associated with high histological grade in the familial group (p = 0.013, p = 0.025). Various statistical associations between the protein expressions were observed in the sporadic group, while in familial group only few associations were found. Univariate analyses showed that nPARP1 expression is able to discriminate between sporadic and familial tumors (OR 2.80, p = 0.002). Multivariate analyses proved that its overexpression is an independent factor associated with a high risk of sporadic tumor (OR 2.96, p = 0.017). Our findings indicate that nPARP1 expression is an independent factor for sporadic BCs and PARP1 inhibitors could be a promising therapy for different phenotypes.
© 2015 UICC.

Entities:  

Keywords:  BRCA1; BRIT1; PARP1; immunohistochemistry; sporadic and familial breast cancers

Mesh:

Substances:

Year:  2015        PMID: 26205471     DOI: 10.1002/ijc.29699

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.

Authors:  Giuliana De Gregoriis; Juliene Antonio Ramos; Priscila Valverde Fernandes; Giselle Maria Vignal; Rafael Canfield Brianese; Dirce Maria Carraro; Alvaro N Monteiro; Claudio José Struchiner; Guilherme Suarez-Kurtz; Rosane Vianna-Jorge; Marcelo Alex de Carvalho
Journal:  Cancer Biol Ther       Date:  2017-05-05       Impact factor: 4.742

2.  Nuclear PARP1 expression and its prognostic significance in breast cancer patients.

Authors:  Annalisa Mazzotta; Giulia Partipilo; Simona De Summa; Francesco Giotta; Giovanni Simone; Anita Mangia
Journal:  Tumour Biol       Date:  2015-11-27

3.  Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.

Authors:  Xinyi Zhu; Tian Tian; Miao Ruan; Jia Rao; Wentao Yang; Xu Cai; Menghong Sun; Guangqi Qin; Zhonghua Zhao; Jiong Wu; Zhimin Shao; Ruohong Shui; Zhen Hu
Journal:  J Breast Cancer       Date:  2018-09-12       Impact factor: 3.588

4.  DNA Damage Response Genes in Osteosarcoma.

Authors:  Ying Tang; Yan-Xia Liu; Xiuning Huang; Peng Li
Journal:  J Oncol       Date:  2021-11-02       Impact factor: 4.375

5.  NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.

Authors:  Anita Mangia; Emanuela Scarpi; Giulia Partipilo; Laura Schirosi; Giuseppina Opinto; Francesco Giotta; Giovanni Simone
Journal:  Oncotarget       Date:  2017-07-22

6.  Silencing BRIT1 Facilitates the Abilities of Invasiveness and Migration in Trophoblast Cells.

Authors:  Luping Liu; Li Sun; Jing Zheng; Yanchun Wang
Journal:  Med Sci Monit       Date:  2018-10-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.